Division of Sports Medicine, Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, USA.
Coastal Orthopaedics, Bradenton, Florida, USA.
Am J Sports Med. 2023 Apr;51(5):1234-1242. doi: 10.1177/03635465231154601. Epub 2023 Feb 22.
Although initial studies have demonstrated that concentrated bone marrow aspirate (cBMA) injections promote rotator cuff repair (RCR) healing, there are no randomized prospective studies investigating clinical efficacy.
HYPOTHESIS/PURPOSE: To compare outcomes after arthroscopic RCR (aRCR) with and without cBMA augmentation. It was hypothesized that cBMA augmentation would result in statistically significant improvements in clinical outcomes and rotator cuff structural integrity.
Randomized controlled trial; Level of evidence, 1.
Patients indicated for aRCR of isolated 1- to 3-cm supraspinatus tendon tears were randomized to receive adjunctive cBMA injection or sham incision. Bone marrow was aspirated from the iliac crest, concentrated using a commercially available system, and injected at the aRCR site after repair. Patients were assessed preoperatively and serially until 2 years postoperatively via the following functional indices: American Shoulder and Elbow Surgeons (ASES), Single Assessment Numeric Evaluation (SANE), Simple Shoulder Test, 12-Item Short Form Health Survey, and Veterans RAND 12-Item Health Survey. Magnetic resonance imaging (MRI) was performed at 1 year to assess rotator cuff structural integrity according to Sugaya classification. Treatment failure was defined as decreased 1- or 2-year ASES or SANE scores as compared with preoperative baseline, the need for revision RCR, or conversion to total shoulder arthroplasty.
An overall 91 patients were enrolled (control, n = 45; cBMA, n = 46): 82 (90%) completed 2-year clinical follow-up and 75 (82%) completed 1-year MRI. Functional indices significantly improved in both groups by 6 months and were sustained at 1 and 2 years (all < .05). The control group showed significantly greater evidence of rotator cuff retear according to Sugaya classification on 1-year MRI (57% vs 18%; < .001). Treatment failed for 7 patients in each group (control, 16%; cBMA, 15%).
cBMA-augmented aRCR of isolated supraspinatus tendon tears may result in a structurally superior repair but largely fails to significantly improve treatment failure rates and patient-reported clinical outcomes when compared with aRCR alone. Additional study is warranted to investigate the long-term benefits of improved repair quality on clinical outcomes and repair failure rates.
NCT02484950 (ClinicalTrials.gov identifier).
虽然初步研究表明浓缩骨髓抽吸物(cBMA)注射可促进肩袖修复(RCR)愈合,但尚无随机前瞻性研究调查其临床疗效。
假设/目的:比较关节镜下 RCR(aRCR)联合和不联合 cBMA 增强治疗后的结果。假设 cBMA 增强治疗会在临床结果和肩袖结构完整性方面产生统计学上的显著改善。
随机对照试验;证据水平,1 级。
患者因孤立性 1 至 3cm 肩峰下肌腱撕裂而接受 aRCR 治疗,随机分为接受辅助 cBMA 注射或假切口治疗。从髂嵴抽吸骨髓,使用市售系统浓缩,然后在修复后注射到 aRCR 部位。患者在术前和术后连续评估,直到术后 2 年,通过以下功能指标进行评估:美国肩肘外科医师协会(ASES)、单项评估数值评估(SANE)、简易肩部测试、12 项简短健康调查问卷和退伍军人 RAND 12 项健康调查问卷。术后 1 年进行磁共振成像(MRI)检查,根据 Sugaya 分类评估肩袖结构完整性。治疗失败定义为与术前基线相比,1 年或 2 年 ASES 或 SANE 评分下降、需要再次 RCR 或转为全肩关节置换术。
共有 91 例患者入组(对照组,n=45;cBMA 组,n=46):82 例(90%)完成了 2 年的临床随访,75 例(82%)完成了 1 年的 MRI 检查。两组患者的功能指标在 6 个月时均显著改善,且在 1 年和 2 年均持续改善(均<0.05)。对照组在术后 1 年的 MRI 上根据 Sugaya 分类显示出更大比例的肩袖再撕裂(57% vs 18%;<0.001)。两组各有 7 例患者治疗失败(对照组,16%;cBMA 组,15%)。
与单独的 aRCR 相比,联合应用浓缩骨髓抽吸物(cBMA)增强的关节镜下治疗孤立性肩峰下肌腱撕裂可能会导致结构更优的修复,但在很大程度上无法显著降低治疗失败率和患者报告的临床结果。需要进一步研究以探讨改善修复质量对临床结果和修复失败率的长期益处。
NCT02484950(ClinicalTrials.gov 标识符)。